跳至主要内容
临床试验/JPRN-UMIN000022587
JPRN-UMIN000022587已完成未知

Prediction of the pharmacokinetics and adverse events of paritaprevir in patients with hepatitis C virus by magnetic resonance imaging - Prediction of the pharmacokinetics and adverse events of paritaprevir by MRI

Juntendo University Nerima Hospital Department of Gastroenterology0 个研究点目标入组 30 人开始时间: 2016年6月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Y93 NS5A polymorphism (pretreatment resistance-associated variants) in the genotype 1b patients 2) Co-infection with hepatitis B or HIV 3) Evidence of viable hepatocellular carcinoma 4) Child-Pugh score greater than 7 5) Concurrent use of moderate to strong inducers of CYP3A and strong inducers of CYP2C8 reduce efficacy 6) Hypersensitivity to Gd-EOB-DTPA 7) Estimated glomerular filtration rate under 40ml/min/1.73m2

研究者

发起方
Juntendo University Nerima Hospital Department of Gastroenterology

相似试验